Furst D E

Top coauthors of Furst D E

Clements P J (36 papers)

Paulus H E (27 papers)

Seibold J R (17 papers)

Nelson J L (10 papers)

Weinstein A (9 papers)

List of Furst D E publications

2017

Lamba M, Hutmacher M M, Furst D E, Dikranian A, Dowty M E, et al. 2017. "Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib." Clinical pharmacology and therapeutics 101 (6) doi:10.1002/cpt.576

2016

Emery P, Bingham C O, Burmester G R, Bykerk V P, Furst D E, et al. 2016. "Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study." Annals of the rheumatic diseases doi:10.1136/annrheumdis-2015-209057

2015

Furst D E, Shaikh S A, Greenwald M, Bennett B, Davies O, et al. 2015. "Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis." Arthritis care & research 67 (2) doi:10.1002/acr.22496

2014

Khanna D, Tan Ma, Furst D E, Hill N S, McLaughlin V V, et al. 2014. "Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative." Clinical and experimental rheumatology 32 (6 Suppl 86) doi:
Song J, Boscardin W J, Furst D E, Khanna D, Wong W K 2014. "A cautionary tale: dealing with missing data in clinical trials for rheumatic diseases." Clinical and experimental rheumatology 32 (6 Suppl 86) doi:

2013

Furst D E, Clarke A, Fernandes A W, Bancroft T, Gajria K, et al. 2013. "Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population." Lupus 22 (3) doi:10.1177/0961203312474087
Furst D E, Clarke A E, Fernandes A W, Bancroft T, Greth W, Iorga S R 2013. "Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population." Lupus 22 (1) doi:10.1177/0961203312463110

2012

Saggar Rajeev, Khanna D, Shapiro S, Furst D E, Maranian P, et al. 2012. "Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study." Arthritis and rheumatism 64 (12) doi:10.1002/art.34614
Merkel P A, Silliman N P, Clements P J, Denton C P, Furst D E, et al. 2012. "Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis." Arthritis and rheumatism 64 (10) doi:10.1002/art.34427

2011

Avouac J, Fransen J, Walker U A, Riccieri V, Smith V, et al. 2011. "Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group." Annals of the rheumatic diseases 70 (3) doi:10.1136/ard.2010.136929
Wong Weng Kee, Boscardin W J, Postlethwaite A E, Furst D E 2011. "Handling missing data issues in clinical trials for rheumatic diseases." Contemporary clinical trials 32 (1) doi:10.1016/j.cct.2010.09.001

2010

Saggar R, Khanna D, Furst D E, Belperio J A, Park G S, et al. 2010. "Systemic sclerosis and bilateral lung transplantation: a single centre experience." The European respiratory journal 36 (4) doi:10.1183/09031936.00139809
Atamas S P, Luzina I G, Ingels J, Choi J, Wong W K, et al. 2010. "Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma)." Clinical and experimental immunology 161 (3) doi:10.1111/j.1365-2249.2010.04189.x
Seibold J R, Denton C P, Furst D E, Guillevin L, Rubin L J, et al. 2010. "Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis." Arthritis and rheumatism 62 (7) doi:10.1002/art.27466
Avouac Jerome, Walker Ulrich, Tyndall Alan, Kahan André, Matucci-Cerinic Marco, et al. 2010. "Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database." The Journal of rheumatology 37 (7) doi:10.3899/jrheum.091165
Morgacheva O, Furst D E 2010. "Use of MTX in the elderly and in patients with compromised renal function." Clinical and experimental rheumatology 28 (5 Suppl 61) doi:
Weng H H, Ranganath V K, Oh M, Park G S, Khanna D, et al. 2010. "Differences in presentation of younger and older systemic sclerosis patients in clinical trials." Clinical and experimental rheumatology 28 (5 Suppl 62) doi:

2009

Matucci-Cerinic M, Allanore Y, Czirják L, Tyndall A, Müller-Ladner U, et al. 2009. "The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy." Annals of the rheumatic diseases 68 (9) doi:10.1136/ard.2008.106302
Mease P J, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, et al. 2009. "Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study." Annals of the rheumatic diseases 68 (8) doi:10.1136/ard.2008.089375
Avouac J, Kowal-Bielecka O, Landewe R, Chwiesko S, Miniati I, et al. 2009. "European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research." Annals of the rheumatic diseases 68 (5) doi:10.1136/ard.2008.095299
Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, et al. 2009. "EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)." Annals of the rheumatic diseases 68 (5) doi:10.1136/ard.2008.096677
Furst D E, Chang H, Greenberg J D, Ranganath V K, Reed G, et al. 2009. "Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry." Clinical and experimental rheumatology 27 (4) doi:

2008

Furst D E 2008. "Outcome measures in rheumatologic clinical trials and systemic sclerosis." Rheumatology (Oxford, England) 47 Suppl 5 doi:10.1093/rheumatology/ken269
Seibold J R, Tyndall A, Furst D E 2008. "Trial design: how must we move ahead?" Rheumatology (Oxford, England) 47 Suppl 5 doi:10.1093/rheumatology/ken312
Behr J, Furst D E 2008. "Pulmonary function tests." Rheumatology (Oxford, England) 47 Suppl 5 doi:10.1093/rheumatology/ken313
Yao Q, Furst D E 2008. "Autoinflammatory diseases: an update of clinical and genetic aspects." Rheumatology (Oxford, England) 47 (7) doi:10.1093/rheumatology/ken118
Taylor W J, Schumacher H R, Baraf H S B, Chapman P, Stamp L, et al. 2008. "A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout." Annals of the rheumatic diseases 67 (6) doi:10.1136/ard.2007.079970
Khanna D, Lovell D J, Giannini E, Clements P J, Merkel P A, et al. 2008. "Development of a provisional core set of response measures for clinical trials of systemic sclerosis." Annals of the rheumatic diseases 67 (5) doi:10.1136/ard.2007.078923
Furst D E, Halbert R J, Bingham C O, Fukudome S, Anderson L, et al. 2008. "Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel." Rheumatology (Oxford, England) 47 (2) doi:10.1093/rheumatology/kem326

2007

Brune K, Furst D E 2007. "Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?" Rheumatology (Oxford, England) 46 (6) doi:10.1093/rheumatology/kem070
Buch M H, Denton C P, Furst D E, Guillevin L, Rubin L J, et al. 2007. "Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test." Annals of the rheumatic diseases 66 (2) doi:10.1136/ard.2006.054866

2006

Khanna D, Furst D E, Hays R D, Park G S, Wong W K, et al. 2006. "Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study." Annals of the rheumatic diseases 65 (10) doi:10.1136/ard.2005.050187
Kavanaugh A, Antoni C E, Gladman D, Wassenberg S, Zhou B, et al. 2006. "The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year." Annals of the rheumatic diseases 65 (8) doi:10.1136/ard.2005.045658
Weinblatt M E, Keystone E C, Furst D E, Kavanaugh A F, Chartash E K, Segurado O G 2006. "Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study." Annals of the rheumatic diseases 65 (6) doi:10.1136/ard.2005.044404

2005

Lambert N C, Pang J M, Yan Z, Erickson T D, Stevens A M, et al. 2005. "Male microchimerism in women with systemic sclerosis and healthy women who have never given birth to a son." Annals of the rheumatic diseases 64 (6) doi:10.1136/ard.2004.029314
Smolen J S, Han C, Bala M, Maini R N, Kalden J R, et al. 2005. "Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study." Arthritis and rheumatism 52 (4) doi:10.1002/art.20982
Loubière L S, Lambert N C, Madeleine M M, Porter A J, Mullarkey M E, et al. 2005. "HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women." Rheumatology (Oxford, England) 44 (3) doi:10.1093/rheumatology/keh489
van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, et al. 2005. "A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis." Annals of the rheumatic diseases 64 (1) doi:10.1136/ard.2003.020347

2004

Yocum D E, Furst D E, Bensen W G, Burch F X, Borton M A, et al. 2004. "Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience." Rheumatology (Oxford, England) 43 (8) doi:10.1093/rheumatology/keh155
Breedveld F C, Emery P, Keystone E, Patel K, Furst D E, et al. 2004. "Infliximab in active early rheumatoid arthritis." Annals of the rheumatic diseases 63 (2) doi:

2001

Furst D E, Keystone E C, Breedveld F C, Kalden J R, Smolen J S, et al. 2001. "Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)." Annals of the rheumatic diseases 60 Suppl 3 doi:
Furst D E 2001. "The status of stem cell transplantation for rheumatoid arthritis: a rheumatologist's view." The Journal of rheumatology. Supplement 64 doi:
Lambert N C, Stevens A M, Tylee T S, Erickson T D, Furst D E, Nelson J L 2001. "From the simple detection of microchimerism in patients with autoimmune diseases to its implication in pathogenesis." Annals of the New York Academy of Sciences 945 doi:
Johnson K L, Nelson J L, Furst D E, McSweeney P A, Roberts D J, et al. 2001. "Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis." Arthritis and rheumatism 44 (8) doi:10.1002/1529-0131(200108)44:8<1848::AID-ART323>3.0.CO;2-L
Pope J E, Bellamy N, Seibold J R, Baron M, Ellman M, et al. 2001. "A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma." Arthritis and rheumatism 44 (6) doi:10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I
Furst D E, Clements P J, Wong W K, Mayes M D, Wigley F, et al. 2001. "Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial." Rheumatology (Oxford, England) 40 (6) doi:
Woodworth T G, Furst D E, Strand V, Kempeni J, Fenner H, et al. 2001. "Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies." The Journal of rheumatology 28 (5) doi:
Clements P J, Wong W K, Hurwitz E L, Furst D E, Mayes M, et al. 2001. "The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial." Arthritis and rheumatism 44 (3) doi:10.1002/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q
Furst D E, Manning D C 2001. "Future directions in pain management." Clinical and experimental rheumatology 19 (6 Suppl 25) doi:
Gavino E S, Furst D E 2001. "Recombinant relaxin: a review of pharmacology and potential therapeutic use." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 15 (9) doi:
Furst D E, Clements P J 2001. "D-penicillamine is not an effective treatment in systemic sclerosis." Scandinavian journal of rheumatology 30 (4) doi:

2000

Viganego F, Nash R, Furst D E 2000. "Bone marrow transplantation in the treatment of systemic sclerosis." Current rheumatology reports 2 (6) doi:
Furst D E, Tyndall A 2000. "Stem cell transplantation in systemic sclerosis: rationale and status report." The Israel Medical Association journal : IMAJ 2 (12) doi:
Lipsky P E, van der Heijde D M, St Clair E W, Furst D E, Breedveld F C, et al. 2000. "Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group." The New England journal of medicine 343 (22) doi:10.1056/NEJM200011303432202
Clements P J, Hurwitz E L, Wong W K, Seibold J R, Mayes M, et al. 2000. "Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial." Arthritis and rheumatism 43 (11) doi:10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q
Furst D E 2000. "Rational therapy in the treatment of systemic sclerosis." Current opinion in rheumatology 12 (6) doi:
Lambert N C, Distler O, Müller-Ladner U, Tylee T S, Furst D E, Nelson J L 2000. "HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men." Arthritis and rheumatism 43 (9) doi:10.1002/1529-0131(200009)43:9<2005::AID-ANR11>3.0.CO;2-#
Hillson J L, Furst D E 2000. "Rofecoxib." Expert opinion on pharmacotherapy 1 (5) doi:10.1517/14656566.1.5.1053
Seibold J R, Korn J H, Simms R, Clements P J, Moreland L W, et al. 2000. "Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial." Annals of internal medicine 132 (11) doi:
Lambert N C, Evans P C, Hashizumi T L, Maloney S, Gooley T, et al. 2000. "Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity." Journal of immunology (Baltimore, Md. : 1950) 164 (11) doi:

1999

Furst D E 1999. "Pharmacology and efficacy of cyclooxygenase (COX) inhibitors." The American journal of medicine 107 (6A) doi:
van Riel P L, Haagsma C J, Furst D E 1999. "Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis." Baillière's best practice & research. Clinical rheumatology 13 (4) doi:10.1053/berh.1999.0054
Furst D E 1999. "Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors." Rheumatology (Oxford, England) 38 Suppl 2 doi:
Furst D E, Keystone E, Maini R N, Smolen J S 1999. "Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis." Rheumatology (Oxford, England) 38 Suppl 2 doi:
Clements P J, Wong W K, Hurwitz E L, Furst D E, Mayes M, et al. 1999. "Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis." Arthritis and rheumatism 42 (11) doi:10.1002/1529-0131(199911)42:11<2372::AID-ANR16>3.0.CO;2-J
Felson D T, LaValley M P, Baldassare A R, Block J A, Caldwell J R, et al. 1999. "The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial." Arthritis and rheumatism 42 (10) doi:10.1002/1529-0131(199910)42:10<2153::AID-ANR16>3.0.CO;2-W
Maloney S, Smith A, Furst D E, Myerson D, Rupert K, et al. 1999. "Microchimerism of maternal origin persists into adult life." The Journal of clinical investigation 104 (1) doi:10.1172/JCI6611
Clements P J, Furst D E, Wong W K, Mayes M, White B, et al. 1999. "High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial." Arthritis and rheumatism 42 (6) doi:10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7
Moreland L W, Schiff M H, Baumgartner S W, Tindall E A, Fleischmann R M, et al. 1999. "Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial." Annals of internal medicine 130 (6) doi:
Evans P C, Lambert N, Maloney S, Furst D E, Moore J M, Nelson J L 1999. "Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma." Blood 93 (6) doi:
Molenaar E T, Boers M, van der Heijde D M, Alarcón G, Bresnihan B, et al. 1999. "Imaging in rheumatoid arthritis: results of group discussions." The Journal of rheumatology 26 (3) doi:
Furst D E, Lindsley H, Baethge B, Botstein G R, Caldwell J, et al. 1999. "Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension." Arthritis and rheumatism 42 (2) doi:10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J
Münster T, Furst D E 1999. "Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA)." Clinical and experimental rheumatology 17 (6 Suppl 18) doi:

1998

Furst D E 1998. "Perspectives on the cyclooxygenase-2/ cyclooxygenase-1 hypothesis." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 4 (5 Suppl) doi:
Wallis W J, Furst D E, Strand V, Keystone E 1998. "Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective." Rheumatic diseases clinics of North America 24 (3) doi:
Huang S C, Jiang R, Hufnagle W O, Furst D E, Wilske K R, Milner E C 1998. "VH usage and somatic hypermutation in peripheral blood B cells of patients with rheumatoid arthritis (RA)." Clinical and experimental immunology 112 (3) doi:
Wigley F M, Korn J H, Csuka M E, Medsger T A, Rothfield N F, et al. 1998. "Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study." Arthritis and rheumatism 41 (4) doi:10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I
Furst D E 1998. "Update on clinical trials in the rheumatic diseases." Current opinion in rheumatology 10 (2) doi:
Nelson J L, Furst D E, Maloney S, Gooley T, Evans P C, et al. 1998. "Microchimerism and HLA-compatible relationships of pregnancy in scleroderma." Lancet 351 (9102) doi:10.1016/S0140-6736(97)08357-8
Seibold J R, Clements P J, Furst D E, Mayes M D, McCloskey D A, et al. 1998. "Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis." The Journal of rheumatology 25 (2) doi:
Caldwell J R, Furst D E, Smith A L, Clark J A, Bonebrake R A, et al. 1998. "Flare during drug withdrawal as a method to support efficacy in rheumatoid arthritis: amiprilose hydrochloride as an example in a double blind, randomized study." The Journal of rheumatology 25 (1) doi:
Furst D E, Clements P J, Steen V D, Medsger T A, Masi A T, et al. 1998. "The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis." The Journal of rheumatology 25 (1) doi:

1997

Furst D E 1997. "The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases." British journal of rheumatology 36 (11) doi:
Hillson J L, Furst D E 1997. "Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design." Rheumatic diseases clinics of North America 23 (4) doi:
Furst D E 1997. "Meloxicam: selective COX-2 inhibition in clinical practice." Seminars in arthritis and rheumatism 26 (6 Suppl 1) doi:
Sullivan K M, Furst D E 1997. "The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases." The Journal of rheumatology. Supplement 48 doi:
Furst D E, Clements P J 1997. "Hypothesis for the pathogenesis of systemic sclerosis." The Journal of rheumatology. Supplement 48 doi:
Nash R A, McSweeney P A, Storb R, Nelson J L, Gauthier J, et al. 1997. "Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease." The Journal of rheumatology. Supplement 48 doi:
McSweeney P A, Nash R A, Storb R, Furst D E, Gauthier J, Sullivan K M 1997. "Autologous stem cell transplantation for autoimmune diseases: issues in protocol development." The Journal of rheumatology. Supplement 48 doi:
Clements P J, Furst D E 1997. "Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation." The Journal of rheumatology. Supplement 48 doi:
van Gestel A M, Haagsma C J, Furst D E, van Riel P L 1997. "Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs)." Baillière's clinical rheumatology 11 (1) doi:
Furst D E 1997. "From disease modification to disease control in rheumatoid arthritis." Clinical and experimental rheumatology 15 Suppl 17 doi:

1996

Wallace D J, Basbug E, Schwartz E, Clements P, Metzger A L, et al. 1996. "A Comparison of Systemic Lupus Erythematosus and Scleroderma Patients with and without Silicone Breast Implants." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2 (5) doi:
Furst D E 1996. "Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases." Lupus 5 Suppl 1 doi:
Kremer J M, Furst D E, Weinblatt M E, Blotner S D 1996. "Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis." The Journal of rheumatology 23 (3) doi:
Furst D E 1996. "Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis." The Journal of rheumatology. Supplement 44 doi:

1995

Gardner G, Furst D E 1995. "Disease-modifying antirheumatic drugs. Potential effects in older patients." Drugs & aging 7 (6) doi:
Furst D E 1995. "Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard." Baillière's clinical rheumatology 9 (4) doi:
Furst D E 1995. "Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis." British journal of rheumatology 34 Suppl 2 doi:
Dayton C S, Schwartz D A, Sprince N L, Yagla S J, Davis C S, et al. 1995. "Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis." American journal of respiratory and critical care medicine 151 (4) doi:10.1164/ajrccm.151.4.7697251

1994

Furst D E, Brooks P, Malaviya A N, Mody G M 1994. "DC-ART: decreased inflammatory synovitis." The Journal of rheumatology. Supplement 41 doi:
Furst D E 1994. "Should methotrexate be used to treat early rheumatoid arthritis?" Seminars in arthritis and rheumatism 23 (6 Suppl 2) doi:
Furst D E 1994. "Predictors of worsening clinical variables and outcomes in rheumatoid arthritis." Rheumatic diseases clinics of North America 20 (2) doi:
Cohick C B, Furst D E, Quagliata S, Corcoran K A, Steere K J, et al. 1994. "Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein." The Journal of laboratory and clinical medicine 123 (5) doi:
Kremer J M, Alarcón G S, Lightfoot R W, Willkens R F, Furst D E, et al. 1994. "Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology." Arthritis and rheumatism 37 (3) doi:
Saag K G, Koehnke R, Caldwell J R, Brasington R, Burmeister L F, et al. 1994. "Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events." The American journal of medicine 96 (2) doi:
Tashkin D P, Clements P J, Wright R S, Gong H, Simmons M S, et al. 1994. "Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis." Chest 105 (2) doi:
Clements P J, Lachenbruch P A, Furst D E, Maxwell M, Danovitch G, Paulus H E 1994. "Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup." Arthritis and rheumatism 37 (1) doi:

1993

Furst D E 1993. "Optimizing combination chemotherapy for rheumatoid arthritis." Annals of the New York Academy of Sciences 696 doi:
Furst D E 1993. "Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a protypic example." Seminars in arthritis and rheumatism 23 (2 Suppl 1) doi:
Rooney T W, Furst D E, Koehnke R, Burmeister L 1993. "Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate." The Journal of rheumatology 20 (8) doi:
Furst D E, Anderson W 1993. "Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis." Arthritis and rheumatism 36 (6) doi:
Sharp J T, Wolfe F, Corbett M, Isomaki H, Mitchell D M, et al. 1993. "Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?" Annals of the rheumatic diseases 52 (5) doi:
Furst D E 1993. "Methotrexate: new mechanisms and old toxicities." Agents and actions. Supplements 44 doi:

1992

Alarcón G S, López-Méndez A, Walter J, Boerbooms A M, Russell A S, et al. 1992. "Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis." The Journal of rheumatology 19 (12) doi:
Furst D E 1992. "Toxicity of antirheumatic medications in children with juvenile arthritis." The Journal of rheumatology. Supplement 33 doi:
Landas S K, Mitros F A, Furst D E, LaBrecque D R 1992. "Lipogranulomas and gold in the liver in rheumatoid arthritis." The American journal of surgical pathology 16 (2) doi:

1991

Clements P J, Lachenbruch P A, Furst D E, Paulus H E, Sterz M G 1991. "Cardiac score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis." Arthritis and rheumatism 34 (11) doi:
Caldwell J R, Furst D E 1991. "The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis." Seminars in arthritis and rheumatism 21 (1) doi:

1990

Furst D E, Erikson N, Clute L, Koehnke R, Burmeister L F, Kohler J A 1990. "Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis." The Journal of rheumatology 17 (12) doi:
Fries J F, Singh G, Lenert L, Furst D E 1990. "Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis." Arthritis and rheumatism 33 (11) doi:
Furst D E 1990. "Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs fail." Seminars in arthritis and rheumatism 20 (2) doi:
Furst D E, Herman R A, Koehnke R, Ericksen N, Hash L, et al. 1990. "Effect of aspirin and sulindac on methotrexate clearance." Journal of pharmaceutical sciences 79 (9) doi:
Clements P J, Lachenbruch P A, Ng S C, Simmons M, Sterz M, Furst D E 1990. "Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis." Arthritis and rheumatism 33 (8) doi:
Clements P J, Peter J B, Agopian M S, Telian N S, Furst D E 1990. "Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil." The Journal of rheumatology 17 (7) doi:
Nuernberg B, Koehnke R, Solsky M, Hoffman J, Furst D E 1990. "Biliary elimination of low-dose methotrexate in humans." Arthritis and rheumatism 33 (6) doi:
Furst D E 1990. "Rheumatoid arthritis. Practical use of medications." Postgraduate medicine 87 (3) doi:
Torres M A, Furst D E 1990. "Treatment of generalized systemic sclerosis." Rheumatic diseases clinics of North America 16 (1) doi:
De Keyser L, Narhi D C, Furst D E, Huberman A K, Ross R, et al. 1990. "Thyroid dysfunction in a prospectively followed series of patients with progressive systemic sclerosis." Journal of endocrinological investigation 13 (2) doi:
Furst D E 1990. "Rational use of disease-modifying antirheumatic drugs." Drugs 39 (1) doi:

1989

Clegg D O, Furst D E, Tolman K G, Pogue R 1989. "Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis." The Journal of rheumatology 16 (8) doi:
Furst D E, Clements P J, Hillis S, Lachenbruch P A, Miller B L, et al. 1989. "Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study." Arthritis and rheumatism 32 (5) doi:
Straniero N R, Furst D E 1989. "Environmentally-induced systemic sclerosis-like illness." Baillière's clinical rheumatology 3 (1) doi:
Furst D E, Koehnke R, Burmeister L F, Kohler J, Cargill I 1989. "Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis." The Journal of rheumatology 16 (3) doi:
Ng S C, Clements P J, Berquist W E, Furst D E, Paulus H E 1989. "Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease." Arthritis and rheumatism 32 (2) doi:
Herman R A, Veng-Pedersen P, Hoffman J, Koehnke R, Furst D E 1989. "Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients." Journal of pharmaceutical sciences 78 (2) doi:

1988

Furst D E 1988. "Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications." The Journal of rheumatology. Supplement 17 doi:
el-Khoury G Y, Larson R K, Kathol M H, Berbaum K S, Furst D E 1988. "Seronegative and seropositive rheumatoid arthritis: radiographic differences." Radiology 168 (2) doi:
Furst D E, Caldwell J R, Klugman M P, Enthoven D, Rittweger K, et al. 1988. "Serum concentration and dose-response relationships for carprofen in rheumatoid arthritis." Clinical pharmacology and therapeutics 44 (2) doi:
Furst D E 1988. "The basis for variability of response to anti-rheumatic drugs." Baillière's clinical rheumatology 2 (2) doi:
Radia M, Furst D E 1988. "Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis." The Journal of rheumatology 15 (2) doi:
Day R O, Furst D E, Dromgoole S H, Paulus H E 1988. "Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers." Biopharmaceutics & drug disposition 9 (3) doi:

1987

Rooney T W, Lorber A, Veng-Pedersen P, Herman R A, Meehan R, et al. 1987. "Gold pharmacokinetics in breast milk and serum of a lactating woman." The Journal of rheumatology 14 (6) doi:
Furst D E, Sarkissian E, Blocka K, Cassell S, Dromgoole S, et al. 1987. "Serum concentrations of salicylate and naproxen during concurrent therapy in patients with rheumatoid arthritis." Arthritis and rheumatism 30 (10) doi:
Rupp P A, Mellinger S, Kohler J, Dorsey J K, Furst D E 1987. "Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker." The Journal of rheumatology 14 (4) doi:
Greenwald G I, Tashkin D P, Gong H, Simmons M, Duann S, et al. 1987. "Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study." The American journal of medicine 83 (1) doi:
Furst D E, Blocka K, Cassell S, Dromgoole S, Harris E R, et al. 1987. "A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimens." The Journal of rheumatology 14 (2) doi:
Zamost B J, Hirschberg J, Ippoliti A F, Furst D E, Clements P J, Weinstein W M 1987. "Esophagitis in scleroderma. Prevalence and risk factors." Gastroenterology 92 (2) doi:
Furst D E, Blocka K, Cassell S, Harris E R, Hirschberg J M, et al. 1987. "A controlled study of concurrent therapy with a nonacetylated salicylate and naproxen in rheumatoid arthritis." Arthritis and rheumatism 30 (2) doi:
Grigor R R, Spitz P W, Furst D E 1987. "Salicylate toxicity in elderly patients with rheumatoid arthritis." The Journal of rheumatology 14 (1) doi:
Seeger M W, Furst D E 1987. "Effects of splinting in the treatment of hand contractures in progressive systemic sclerosis." The American journal of occupational therapy : official publication of the American Occupational Therapy Association 41 (2) doi:

1986

Blocka K L, Paulus H E, Furst D E 1986. "Clinical pharmacokinetics of oral and injectable gold compounds." Clinical pharmacokinetics 11 (2) doi:

1985

Furst D E 1985. "Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis." The Journal of rheumatology. Supplement 12 Suppl 12 doi:
Williams H J, Furst D E, Dahl S L, Steen V D, Marks C, et al. 1985. "Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis." Arthritis and rheumatism 28 (3) doi:
Furst D E 1985. "Significance of NSAID serum to response relationships." Agents and actions. Supplements 17 doi:
Furst D E 1985. "Synovial fluid kinetics of non-steroidal anti-inflammatory drugs." Agents and actions. Supplements 17 doi:
Brasington R D, Furst D E 1985. "Pulmonary disease in systemic lupus erythematosus." Clinical and experimental rheumatology 3 (3) doi:

1984

Furst D E, Clements P J, Saab M, Sterz M G, Paulus H E 1984. "Clinical and serological comparison of 17 chronic progressive systemic sclerosis (PSS) and 17 CREST syndrome patients matched for sex, age, and disease duration." Annals of the rheumatic diseases 43 (6) doi:
Dromgoole S H, Furst D E, Paulus H E 1984. "Metabolism of salsalate in normal subjects." Journal of pharmaceutical sciences 73 (11) doi:
Furst D E 1984. "Use of ibuprofen in unusual circumstances." The American journal of medicine 77 (1A) doi:
Furst D E, Obrodovic M, Barnett E V, Clements P J, Paulus H E 1984. "Case control study of antibodies to ENA in progressive systemic sclerosis patients." The Journal of rheumatology 11 (3) doi:
Furst D E, Dromgoole S H 1984. "Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST)." Clinical rheumatology 3 Suppl 1 doi:

1983

Tozer T N, Gambertoglio J G, Furst D E, Avery D S, Holford N H 1983. "Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans." Journal of pharmaceutical sciences 72 (12) doi:
Dromgoole S H, Cassell S, Furst D E, Paulus H E 1983. "Availability of salicylate from salsalate and aspirin." Clinical pharmacology and therapeutics 34 (4) doi:
Furst D E, Dromgoole S H, Desiraju R K, Paulus H E 1983. "Clinical pharmacology of tolmetin: comparisons in rheumatoid arthritis patients and normal volunteers." Journal of clinical pharmacology 23 (7) doi:
Williams H J, Ward J R, Reading J C, Egger M J, Grandone J T, et al. 1983. "Low-dose D-penicillamine therapy in rheumatoid arthritis. A controlled, double-blind clinical trial." Arthritis and rheumatism 26 (5) doi:
Furst D E 1983. "Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis." Pharmacotherapy 3 (5) doi:
Dobrinska M R, Furst D E, Spiegel T, Vincek W C, Tompkins R, et al. 1983. "Biliary secretion of sulindac and metabolites in man." Biopharmaceutics & drug disposition 4 (4) doi:
Furst D E, Dromgoole S H, Fow S, Landaw E M 1983. "Comparison of tolmetin kinetics in rheumatoid arthritis and matched healthy controls." Journal of clinical pharmacology 23 (11-12) doi:

1982

Dromgoole S H, Furst D E, Desiraju R K, Nayak R K, Kirschenbaum M A, Paulus H E 1982. "Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis." Clinical pharmacology and therapeutics 32 (3) doi:
Day R O, Furst D E, Dromgoole S H, Kamm B, Roe R, Paulus H E 1982. "Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis." Clinical pharmacology and therapeutics 31 (6) doi:
Blocka K, Furst D E, Landaw E, Dromgoole S, Blomberg A, Paulus H E 1982. "Single dose pharmacokinetics of auranofin in rheumatoid arthritis." The Journal of rheumatology. Supplement 8 doi:

1981

Furst D E, Davis J A, Clements P J, Chopra S K, Theofilopoulos A N, Chia D 1981. "Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis." Arthritis and rheumatism 24 (11) doi:
Day R O, Dromgoole S H, Furst D E, Hignite C, Paulus H E 1981. "Formation of methyl ester of salicyluric acid during quantitation of salicyluric acid in urine by high-pressure liquid chromatography." Journal of pharmaceutical sciences 70 (9) doi:
Clements P J, Furst D E, Cabeen W, Tashkin D, Paulus H E, Roberts N 1981. "The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS)." The American journal of medicine 71 (1) doi:
Bassett L W, Blocka K L, Furst D E, Clements P J, Gold R H 1981. "Skeletal findings in progressive systemic sclerosis (scleroderma)." AJR. American journal of roentgenology 136 (6) doi:10.2214/ajr.136.6.1121
Williams R L, Furst D E, Mandel H G, Nicoll D, Konikoff J J, Benet L Z 1981. "Effects of indomethacin and carprofen on renal homeostasis in rheumatoid arthritis patients and in healthy individuals." Journal of clinical pharmacology 21 (11-12 Pt 1) doi:
Liebling M R, Leib E, McLaughlin K, Blocka K, Furst D E, et al. 1981. "Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial." Annals of internal medicine 94 (1) doi:
Roberts N K, Cabeen W R, Moss J, Clements P J, Furst D E 1981. "The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis." Annals of internal medicine 94 (1) doi:

1980

Herzog P, Clements P J, Roberts N K, Furst D E, Johnson C E, Feig S A 1980. "Case report: progressive systemic sclerosis-like syndrome after bone marrow transplantation. Clinical, immunologic, and pathologic findings." The Journal of rheumatology 7 (1) doi:

1979

Furst D E, Tozer T N, Melmon K L 1979. "Salicylate clearance, the resultant of protein binding and metabolism." Clinical pharmacology and therapeutics 26 (3) doi:
Furst D E, Clements P J, Graze P, Gale R, Roberts N 1979. "A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. A model for scleroderma?" Arthritis and rheumatism 22 (8) doi:
Furst D E, Clements P J, Harris R, Ross M, Levy J, Paulus H E 1979. "Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine." Annals of the rheumatic diseases 38 (4) doi:

1978

Clements P J, Furst D E, Campion D S, Bohan A, Harris R, et al. 1978. "Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations." Arthritis and rheumatism 21 (1) doi:
Weinkam R J, Wen J H, Furst D E, Levin V A 1978. "Analysis for 1,3-bis(2-chloroethyl)-1-nitrosourea by chemical ionization mass spectrometry." Clinical chemistry 24 (1) doi:

1977

Furst D E, Gupta N, Paulus H E 1977. "Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formation." The Journal of clinical investigation 60 (1) doi:10.1172/JCI108766
White S C, Frey N W, Blaschke D D, Ross M D, Clements P J, et al. 1977. "Oral radiographic changes in patients with progressive systemic sclerosis (scleroderma)." Journal of the American Dental Association (1939) 94 (6) doi:
Furst D E, Levine S, Srinivasan R, Metzger A L, Bangert R, Paulus H E 1977. "A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis." Arthritis and rheumatism 20 (8) doi:

1975

Furst D E, Paulus H E 1975. "Lack of effect of rheumatoid arthritis on clonixin metabolism." Clinical pharmacology and therapeutics 17 (5) doi: